Englewood Lab (A950140) Q2 2025 earnings summary

Executive summary

• Operates as a cosmetics ODM/OEM manufacturer in the US, specializing in skincare and functional cosmetics, with a strong R&D focus and global certifications.

• Main subsidiary is Englewood Lab Korea, fully owned and consolidated.

• Listed on KOSDAQ since 2016, with stable management and no major changes in capital or business scope.

Financial highlights

• H1 2025 consolidated revenue: $70.2M, down from $133.6M in FY2024 and $158.4M in FY2023.

• H1 2025 operating income: $10.3M; net income: $4.3M; EPS: $0.22.

• Cash and equivalents at period end: $18.8M; total assets: $156.6M; equity: $103.6M.

• Gross margin for H1 2025: 25.2%.

• Dividend payout ratio (2024): 10.2%.

Outlook and guidance

• Focus on expanding into premium skincare and global brand markets.

• Continued investment in R&D and regulatory compliance to maintain competitive edge.